Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 oral PCSK9 inhibitor dose-response study in ASCVD or ASCVD-risk patients needing additional LDL-C lowering
NL-OMON52178Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Oct 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of NNC0385-0434 in atherosclerotic disease and hypercholesterolemia (7 arms), sponsored by Novo Nordisk. Primary endpoint: Percent change in LDL-cholesterol. Started Oct 2021; status: active, not recruiting.
02
Drugs
NNC0385-0434
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on NL-OMON52178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52178.